Allogeneic Cell Therapy
in Critical Limb Ischemia (CLI)
Annual health expenditures related to the pathology represent more than $ 4 billion in the US (2011). Overall costs per patient increased by 63%, from $ 12,560 in 2001 to $ 20,517 in 2011.
A huge unmet medical need
A highly morbid disease, aggravated in diabetics and smokers, Critical Limb Ischemia is the end stage of Peripheral Arterial Disease. It is characterized by ischemic rest pain, tissue necrosis, ulcers, or gangrene in the presence of objective hemodynamic evidence of arterial insufficiency. The available treatment options available are very limited when surgical or catheter revascularization is no longer possible.
CLI Phase IIa
Co-funded in partnership with the University Hospital of Reims, a Phase IIa clinical trial will evaluate the tolerance and the preliminary efficacy of an intramuscular injection of a single dose, a double dose of MSC or a placebo , in 30 patients with critical limb ischemia, after a revascularization procedure.